血管内支架与支架联合125I粒子条治疗上腔静脉综合征  

Intravascular stent versus stent combined with~(125)I seed strip implantation in the treatment of superior vena cava syndrome

作　　者：秦闫威 马鸿儒 陈节 李均彪 李艳 王勇 许伟 QIN Yanwei;MA Hongru;CHEN Jie;LI Junbiao;LI Yan;WANG Yong;XU Wei(Department of Interventional Radiology,Affiliated Hospital of Xuzhou Medical University,Xuzhou,Jiangsu Province 221006,China)

机构地区：[1]徐州医科大学附属医院介入放射科,江苏徐州221006

出　　处：《介入放射学杂志》2024年第6期632-635,共4页Journal of Interventional Radiology

摘　　要：目的评价血管内支架联合125I粒子条植入治疗恶性肿瘤所致上腔静脉综合征(SVCS)患者的安全性与临床价值。方法回顾性分析徐州医科大学附属医院2017年5月至2022年10月收治的43例SVCS患者的临床资料,其中血管内支架联合125I粒子条植入27例(观察组),单纯血管内支架植入16例(对照组)。比较两组患者的支架通畅率、临床症状缓解率和生存期。结果43例患者手术均成功。观察组术后3个月内支架通畅率与平均生存期为88.7%和39.1周,优于对照组的62.5%和21.8周,差异有统计学意义(P=0.033、0.035)。术后临床症状均得到缓解。结论血管内支架联合125I粒子条植入治疗SVCS安全有效,可作为首选治疗方案。Objective To evaluate the clinical safety and effectiveness of intravascular stent combined with~(125)I seed strip implantation in the treatment of superior vena cava syndrome(SVCS)caused by malignant tumors.Methods The clinical data of 43 patients with SVCS,who were admitted to the Affiliated Hospital of Xuzhou Medical University of China from May 2017 to October 2022,were retrospective analyzed.Of the43 patients,27 received intravascular stent combined with~(125)I seed strip implantation(observation group),and16 received simple intravascular stent implantation(control group).The stent patency rate,clinical symptom relief rate,and survival time were compared between the two groups.Results Successful operation was accomplished in all the 43 patients.In the observation group,the postoperative 3-month stent patency rate and average survival time were 88.7%and 39.1 weeks respectively,which were significantly higher than62.5%and 21.8 weeks respectively in the control group,the differences between the two groups were statistically significant(P=0.033 and P=0.035 respectively).After treatment,all the clinical symptoms were relieved.Conclusion For the treatment of SVCS,intravascular stent combined with~(125)I seed strip implantation is clinically safe and effective,it can be used as the preferred treatment option.

关 键 词：上腔静脉阻塞综合征 125I粒子 血管内支架 

分 类 号：R730.5[医药卫生—肿瘤]